Roche announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lunsumio VELO™ (mosunetuzumab), a subcutaneous (SC) formulation for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The treatment is indicated for those who have received at least two prior lines of systemic therapy.
This milestone marks a significant shift in the delivery of care for follicular lymphoma, a chronic form of non-Hodgkin lymphoma. By moving from a traditional intravenous (IV) infusion to a subcutaneous injection, the administration time is slashed from several hours to approximately one minute.
A New Standard for Patient Convenience
Follicular lymphoma is characterized by a cycle of remissions and relapses, often requiring lifelong management. Traditional treatments can be burdensome, requiring patients to spend half a day in a clinic for infusions.
With this FDA approval, treatment can now be administered in just one minute, which significantly reduces the time patients spend in the clinic and helps to align care with their individual needs and preferences.
Levi Garraway
Key Clinical Advantages
- Fixed Duration: Treatment is given for a set period (as short as six months), unlike “treat-to-progression” therapies that continue indefinitely.
- Outpatient Access: Designed for use in community practice settings, increasing accessibility for patients outside of major academic hospitals.
- Rapid Delivery: Reduced from 2–4 hours (IV) to ~1 minute (SC).
Efficacy and Safety Profile
The approval is based on data from the Phase I/II GO29781 study, which evaluated Lunsumio VELO in patients with third-line or later (3L+) follicular lymphoma. The data demonstrated that the subcutaneous formulation maintained the high efficacy standards set by the original IV version.
| Metric | Outcome (95% CI) |
| Objective Response Rate (ORR) | 75% (64–83%) |
| Complete Response Rate (CR) | 59% (48–69%) |
| Median Duration of Response | 22.4 months |
Safety Considerations
The study reported a manageable safety profile. The most common adverse reactions (≥20%) included injection site reactions, fatigue, rash, and cytokine release syndrome (CRS).
- CRS Incidence: 30% of patients experienced CRS.
- Severity: Most events were low-grade (Grade 1–2: 28%; Grade 3: 2.1%).
- Resolution: CRS events typically occurred during the first cycle and were resolved within a median of two days.
The Road Ahead: Expanding the Portfolio
While this accelerated approval is a major win for patients with advanced disease, Roche is already looking toward earlier lines of treatment. Ongoing Phase III trials include:
- SUNMO Study: Investigating Lunsumio VELO + Polivy® for second-line large B-cell lymphoma.
- MorningLyte Study: Investigating Lunsumio VELO + lenalidomide for previously untreated follicular lymphoma.
As part of the accelerated approval pathway, Roche may be required to conduct confirmatory trials to verify the long-term clinical benefit of this regimen.
Last Modified:
